Matinas BioPharma Holdings, Inc.
MTNB
$0.5571
-$0.0429-7.15%
AMEX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.10M | 2.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.10M | 2.16M |
| Cost of Revenue | 12.72M | 13.78M | 13.97M | 14.49M | 14.69M |
| Gross Profit | -12.72M | -13.78M | -13.97M | -13.39M | -12.53M |
| SG&A Expenses | 9.29M | 9.99M | 10.12M | 10.37M | 10.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.01M | 23.76M | 24.08M | 24.86M | 25.52M |
| Operating Income | -22.01M | -23.76M | -24.08M | -23.77M | -23.36M |
| Income Before Tax | -21.13M | -22.91M | -23.25M | -22.94M | -21.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.13 | -22.91 | -23.25 | -22.94 | -21.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.13M | -22.91M | -23.25M | -22.94M | -21.26M |
| EBIT | -22.01M | -23.76M | -24.08M | -23.77M | -23.36M |
| EBITDA | -21.63M | -23.38M | -23.69M | -23.37M | -22.97M |
| EPS Basic | -4.56 | -5.10 | -5.35 | -5.28 | -4.90 |
| Normalized Basic EPS | -2.85 | -3.19 | -3.34 | -3.30 | -3.06 |
| EPS Diluted | -4.56 | -5.10 | -5.35 | -5.28 | -4.90 |
| Normalized Diluted EPS | -2.85 | -3.19 | -3.34 | -3.30 | -3.06 |
| Average Basic Shares Outstanding | 18.72M | 18.02M | 17.38M | 17.38M | 17.34M |
| Average Diluted Shares Outstanding | 18.72M | 18.02M | 17.38M | 17.38M | 17.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |